Hepatocellular carcinoma (HCC) is a heterogeneous cancer with variable outcomes after treatment. Prognosis of HCC cannot be accurately predicted by current clinical staging systems. Development of prognostic biomarkers is critical to improve treatment outcome. Recent studies indicate that inflammatory and immunological markers might provide reliable prognostic classification in HCC.
- Roberta W. C. Pang
- Ronnie T. P. Poon
